-
Whole_genome_sequencing_of_100_DDD_trios_with_suspected_noncoding_causal_mutations
Study
EGAS00001002452
-
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Study
EGAS00001007709
-
Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients
Study
EGAS50000000334
-
METABRIC
Study
EGAS00000000098
-
Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma
Study
EGAS50000000412
-
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Study
EGAS50000000710
-
Luminal breast epithelial cells from wildtype and BRCA mutation carriers harbor copy number alterations commonly associated with breast cancer
Study
EGAS00001007716
-
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification and exhaustion in multiple myeloma
Study
EGAS50000000304
-
Discovery and validation of an ancillary genomic test of malignancy for primary melanocytic tumors
Study
EGAS50000000887
-
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia
Study
EGAS50000000933
-
Bladder cancer subtyping study across 4 atezo clinical trials
Study
EGAS50000000497
-
The phase II Neo-Pembro trial: neoadjuvant pembrolizumab in stage IV high-grade serous ovarian cancer
Study
EGAS50000000781
-
Analysis of CD20 loss in patients treated with Mosunetuzumab
Study
EGAS50000000151
-
Repeat expansions with small TTTCA insertions in MARCHF6 cause Familial Adult Myoclonus without Epilepsy
Study
EGAS50000000570
-
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients (LuCaP cell line data)
Study
EGAS50000000917
-
Convergent evolution towards CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
Study
EGAS50000000709
-
IDH-wildtype untreated human glioblastoma samples (GB-UK cohort), published in Noorani & Haughey et al 2025.
Study
EGAS00001008126
-
RNAseq: Acquired non-permissive bone marrow microenvironment impairs hematopoietic stem cell proliferation and maintenance and B-cell development post-HSCT
Study
EGAS50000001437
-
ATAC-seq: Acquired non-permissive bone marrow microenvironment impairs hematopoietic stem cell proliferation and maintenance and B-cell development post-HSCT
Study
EGAS50000001438
-
Single-cell Transcriptome Profiling of Treatment-naïve and Post-treatment Colorectal Cancer: Insights into Putative Mechanisms of Chemoresistance
Study
EGAS50000000830
-
Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences
Study
EGAS50000001102
-
Biallelic variants in the non-protein coding minor spliceosome components RNU6ATAC and RNU6ATAC cause syndromic monogenic autoimmune diabetes
Study
EGAS50000001565
-
Confronting historical legacies of biological anthropology in South Africa—Restitution, redress and community-centered science: The Sutherland Nine
Study
EGAS50000000971
-
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Study
EGAS50000001572
-
Distinct evolutionary trajectories of primary high grade serous ovarian cancers revealed through spatial mutational profiling
Study
EGAS00001000547